Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nathan A. Tullos"'
Autor:
Mary A. Carr, Dennis Marcelo, K. Michael Lovell, Angela H. Benton, Nathan A. Tullos, Erin W. Norcross, Brandon Myers, Marcus K. Robbins, Hayley Craddieth, Mary E. Marquart
Publikováno v:
Microorganisms, Vol 10, Iss 4, p 710 (2022)
The role of the pneumococcal polysaccharide capsule is largely unclear for Streptococcus pneumoniae keratitis, an ocular inflammatory disease that develops as a result of bacterial infection of the cornea. In this study, capsule-deficient strains wer
Externí odkaz:
https://doaj.org/article/ef96d674efff4f00861aea60a2182f44
Autor:
Mary A, Carr, Dennis, Marcelo, K Michael, Lovell, Angela H, Benton, Nathan A, Tullos, Erin W, Norcross, Brandon, Myers, Marcus K, Robbins, Hayley, Craddieth, Mary E, Marquart
Publikováno v:
Microorganisms. 10(4)
The role of the pneumococcal polysaccharide capsule is largely unclear for
Autor:
Sidney D Taylor, Melissa E Sanders, Nathan A Tullos, Stephen J Stray, Erin W Norcross, Larry S McDaniel, Mary E Marquart
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61300 (2013)
Streptococcus pneumoniae (pneumococcus) is an opportunistic bacterial pathogen responsible for causing several human diseases including pneumonia, meningitis, and otitis media. Pneumococcus is also a major cause of human ocular infections and is comm
Externí odkaz:
https://doaj.org/article/ee54d51a1e634f9f9be4088090ac7901
Publikováno v:
Nephrology Dialysis Transplantation. 30:584-593
Background Emerging research has identified the endothelin (ET)-1 pathway as a potential target for novel renoprotective therapies. We recently showed that selective ET-A receptor antagonism in chronic renovascular disease (RVD) improves renal functi
Renovascular disease (RVD) induces renal microvascular (MV) rarefaction that drives progressive kidney injury. In previous studies, we showed that renal vascular endothelial growth factor (VEGF) therapy attenuated MV damage, but did not resolve renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb4544bf33ee1d8d099db62cde78406d
https://europepmc.org/articles/PMC4884109/
https://europepmc.org/articles/PMC4884109/
Autor:
Erin W. Norcross, Sidney D. Taylor, Lauren B King, Mary E. Marquart, Melissa E. Sanders, Nathan A. Tullos, Isaiah Tolo
Publikováno v:
Current Eye Research. 35:1142-1147
Compare the efficacy of treatment of pneumococcal keratitis with cholesterol, moxifloxacin, or a mixture of the two (moxifloxacin/cholesterol).New Zealand white rabbits were injected intrastromally with 10(6) colony-forming units (CFU) of a clinical
Percutaneous transluminal renal angioplasty/stenting (PTRAS) is frequently used to treat renal artery stenosis and renovascular disease (RVD); however, renal function is restored in less than one half of the cases. This study was designed to test a n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa60fa2255774eeb98476ee684b5365
https://europepmc.org/articles/PMC4413765/
https://europepmc.org/articles/PMC4413765/
Publikováno v:
The FASEB Journal. 28
Autor:
Hilary W. Thompson, Quincy C. Moore, Isaiah Tolo, Sidney D. Taylor, Mary E. Marquart, Melissa E. Sanders, Nathan A. Tullos, Erin W. Norcross
Publikováno v:
Curr Eye Res
PURPOSE: Bacterial keratitis, without effective antimicrobial treatment, leads to poor patient prognosis. Even after bacterial clearance, the host inflammatory response can contribute to corneal damage. Though Streptococcus pneumoniae (pneumococcus)
Autor:
Sidney D. Taylor, Larry S. McDaniel, Robert L. Burton, Nathan A. Tullos, Sherrina N Dixon, Hilary W. Thompson, Erin W. Norcross, Mary E. Marquart, Rhonda R. Caston, Quincy C. Moore, Melissa E. Sanders, Moon H. Nahm
The purpose of this study was to determine whether active immunization against pneumolysin (PLY), or polysaccharide capsule, protects against the corneal damage associated with Streptococcus pneumoniae keratitis.New Zealand White rabbits were activel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a433f0454513dba8e5c5ef2fa7f293
https://europepmc.org/articles/PMC3302430/
https://europepmc.org/articles/PMC3302430/